凝血因子Ⅺ——抗血栓形成的新靶点
作者: |
1刘惠娜,
1邓常清,
2贺石林
1 湖南中医药大学血管生物学实验室,长沙 410208 2 中南大学湘雅医学院生理学系,长沙 410008 |
通讯: |
邓常清
Email: dchangq@sohu.com |
DOI: | 10.3978/j.issn.2095-6959.2016.06.023 |
基金: | 湖南省教育厅资助科研项目, 15C1026 湖南中医药大学青年教师科研基金课题, 2015-21 |
摘要
近年来血栓性疾病发病率上升,严重危害人类的健康。目前临床使用的抗血栓药物存在出血的毒副作用。大量研究表明,凝血因子Ⅺ(factor Ⅺ,FⅪ)基因剔除或缺陷无出血倾向,却可以抑制闭塞性血栓形成。近年来开展的以FⅪ为靶点的抗血栓研究已取得了一定进展。本文就FⅪ作为抗血栓药物新靶点的依据,FⅪ在血栓形成中的作用及其作为抗血栓药物靶点的研究进展做一综述,以期为研究新的抗血栓药物提供思路。
关键词:
血栓性疾病
凝血因子Ⅺ
抗血栓形成
新靶点
Coagulation factor Ⅺ: a new target for antithrombotic drug
CorrespondingAuthor: DENG Changqing Email: dchangq@sohu.com
DOI: 10.3978/j.issn.2095-6959.2016.06.023
Abstract
In recent years, the incidence of thrombotic diseases is increasing, which is seriously harmful to human health. Existing clinical applications of anticoagulants can cause severe bleeding complications. Recent studies indicate that FⅪ-deficient mice were fully protected from occlusive thrombus without severely prolonged bleeding times. The study of antithrombotic therapy by inhibiting of FⅪ has made remarkable progress. On the basis of FⅪ, a new target for antithrombotic drug, this paper reviews the effect of FⅪ on thrombus formation and the recent progress on FⅪ for antithrombotic drug, and further wish to provide new strategy for development of new antithrombotic drug.